Larvol Delta - Atossa-Therapeutics-Completes-Enrollment-of-Phase-1-Clinical-Study-of-AT301-Nasal-Spray-Being-Developed-for-the-Coronavirus-Causing-COVID

AT-301 - Atossa Therap

https://www.globenewswire.com/news-release/2020/10/19/2110485/0/en/Atossa-Therapeutics-Completes-Enrollment-of-Phase-1-Clinical-Study-of-AT-301-Nasal-Spray-Being-Developed-for-the-Coronavirus-Causing-COVID.html

Oct 19, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next